Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...

Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, ...

Merck will buy Minneapolis-based Bio-Techne Corp. in a deal worth $11.3 billion. Bio-Techne was under pressure from an ...

Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...

After a difficult period in FY22, Bio-Techne has endured a similar fate into the new year. Our previous tactical speculative buy call hasn't played out in the name; unfortunate, but the reality. Here ...

A congressional transaction is when any representative or senator either buys or sells an individual stock. Anyone working in Congress must file a Periodic Transaction Report to inform the public of ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...

Bio-Techne Corporation today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and ...

With a new name and a new CEO, Bio-Techne has begun an aggressive growth strategy to ensure that researchers know not only its flagship brand, R&D Systems, but the company as a whole. One year ago, ...